Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANGO NASDAQ:ANIK NASDAQ:ATRS NASDAQ:SIBN NASDAQ:SRDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGOAngioDynamics$10.50-1.4%$9.41$5.83▼$13.50$426.66M0.64608,140 shs270,586 shsANIKAnika Therapeutics$8.65-0.2%$9.59$7.87▼$26.00$124.72M0.6389,027 shs134,140 shsATRSAntares Pharma$5.59$5.59$3.11▼$5.60$955.06M1.153.29 million shs6 shsSIBNSiBone$15.14-3.6%$16.63$11.70▼$20.05$653.14M0.81422,471 shs474,372 shsSRDXSurmodics$32.37+1.3%$34.14$26.00▼$40.38$462.89M1.37190,924 shs104,169 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGOAngioDynamics0.00%-0.75%+21.44%-1.48%+39.40%ANIKAnika Therapeutics0.00%-3.02%-1.81%-21.96%-64.81%ATRSAntares Pharma0.00%0.00%0.00%0.00%0.00%SIBNSiBone0.00%-3.62%+1.55%-12.44%-0.19%SRDXSurmodics0.00%-1.30%-14.68%+7.00%-18.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGOAngioDynamics$10.50-1.4%$9.41$5.83▼$13.50$426.66M0.64608,140 shs270,586 shsANIKAnika Therapeutics$8.65-0.2%$9.59$7.87▼$26.00$124.72M0.6389,027 shs134,140 shsATRSAntares Pharma$5.59$5.59$3.11▼$5.60$955.06M1.153.29 million shs6 shsSIBNSiBone$15.14-3.6%$16.63$11.70▼$20.05$653.14M0.81422,471 shs474,372 shsSRDXSurmodics$32.37+1.3%$34.14$26.00▼$40.38$462.89M1.37190,924 shs104,169 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGOAngioDynamics0.00%-0.75%+21.44%-1.48%+39.40%ANIKAnika Therapeutics0.00%-3.02%-1.81%-21.96%-64.81%ATRSAntares Pharma0.00%0.00%0.00%0.00%0.00%SIBNSiBone0.00%-3.62%+1.55%-12.44%-0.19%SRDXSurmodics0.00%-1.30%-14.68%+7.00%-18.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGOAngioDynamics 3.00Buy$19.0080.95% UpsideANIKAnika Therapeutics 3.50Strong Buy$18.00108.09% UpsideATRSAntares Pharma 0.00N/AN/AN/ASIBNSiBone 3.00Buy$23.6756.32% UpsideSRDXSurmodics 2.25Hold$43.0032.84% UpsideCurrent Analyst Ratings BreakdownLatest SIBN, SRDX, ANGO, ATRS, and ANIK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025SRDXSurmodicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$25.008/11/2025SRDXSurmodicsBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.007/31/2025ANIKAnika TherapeuticsBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$19.00 ➝ $15.007/16/2025ANGOAngioDynamicsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.007/16/2025ANGOAngioDynamicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.007/16/2025ANGOAngioDynamicsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $17.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGOAngioDynamics$292.50M1.46$0.48 per share21.87$4.51 per share2.33ANIKAnika Therapeutics$114.55M1.09$0.10 per share90.89$10.51 per share0.82ATRSAntares Pharma$183.98M5.19$0.13 per share43.89$1.03 per share5.43SIBNSiBone$167.18M3.91N/AN/A$3.98 per share3.80SRDXSurmodics$126.08M3.67$0.31 per share103.30$8.33 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGOAngioDynamics-$33.99M-$0.83N/AN/AN/A-11.62%-3.20%-2.09%10/2/2025 (Estimated)ANIKAnika Therapeutics-$56.38M-$4.15N/AN/AN/A-48.99%-10.97%-8.51%10/30/2025 (Estimated)ATRSAntares Pharma$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/ASIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)SRDXSurmodics-$11.54M-$1.23N/A40.46N/A-14.59%-2.99%-1.99%11/5/2025 (Estimated)Latest SIBN, SRDX, ANGO, ATRS, and ANIK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/2/2025Q1 2026ANGOAngioDynamics-$0.13N/AN/AN/A$72.69 millionN/A8/8/2025Q3 2025SRDXSurmodics-$0.21$0.06+$0.27-$0.37$28.04 million$29.57 million8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million7/15/2025Q4 2025ANGOAngioDynamics-$0.12-$0.03+$0.09-$0.15$74.26 million$80.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGOAngioDynamicsN/AN/AN/AN/AN/AANIKAnika TherapeuticsN/AN/AN/AN/AN/AATRSAntares PharmaN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ASRDXSurmodicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGOAngioDynamicsN/A2.211.40ANIKAnika TherapeuticsN/A6.185.12ATRSAntares Pharma0.103.082.87SIBNSiBone0.218.387.00SRDXSurmodics0.273.913.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGOAngioDynamics89.43%ANIKAnika Therapeutics91.53%ATRSAntares Pharma50.41%SIBNSiBone98.11%SRDXSurmodics96.63%Insider OwnershipCompanyInsider OwnershipANGOAngioDynamics5.40%ANIKAnika Therapeutics9.64%ATRSAntares Pharma5.90%SIBNSiBone3.90%SRDXSurmodics8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANGOAngioDynamics76040.63 million38.44 millionOptionableANIKAnika Therapeutics30014.42 million13.03 millionOptionableATRSAntares Pharma201170.85 million160.77 millionOptionableSIBNSiBone35043.14 million41.46 millionOptionableSRDXSurmodics45014.30 million13.03 millionOptionableSIBN, SRDX, ANGO, ATRS, and ANIK HeadlinesRecent News About These CompaniesDLD Asset Management LP Cuts Stock Holdings in Surmodics, Inc. $SRDXSeptember 14 at 5:26 AM | marketbeat.comAlliancebernstein L.P. Has $25.93 Million Stake in Surmodics, Inc. $SRDXSeptember 12 at 3:54 AM | marketbeat.com26,700 Shares in Surmodics, Inc. $SRDX Acquired by Wellington Management Group LLPSeptember 3, 2025 | marketbeat.comAlpine Global Management LLC Raises Stock Holdings in Surmodics, Inc. $SRDXSeptember 2, 2025 | marketbeat.comSurmodics, Inc. $SRDX Shares Bought by Angelo Gordon & CO. L.P.September 2, 2025 | marketbeat.comNuveen LLC Takes Position in Surmodics, Inc. $SRDXSeptember 2, 2025 | marketbeat.com7,583 Shares in Surmodics, Inc. $SRDX Purchased by AlphaQuest LLCSeptember 1, 2025 | marketbeat.comDeutsche Bank AG Has $331,000 Stock Holdings in Surmodics, Inc. $SRDXAugust 31, 2025 | marketbeat.comGamco Investors INC. ET AL Cuts Stake in Surmodics, Inc. $SRDXAugust 30, 2025 | marketbeat.comGabelli Funds LLC Increases Holdings in Surmodics, Inc. $SRDXAugust 30, 2025 | marketbeat.comGABELLI & Co INVESTMENT ADVISERS INC. Buys 66,150 Shares of Surmodics, Inc. $SRDXAugust 28, 2025 | marketbeat.comHsbc Holdings PLC Increases Stake in Surmodics, Inc. $SRDXAugust 27, 2025 | marketbeat.comGroupe la Francaise Takes Position in Surmodics, Inc. $SRDXAugust 26, 2025 | marketbeat.comAlgert Global LLC Acquires 20,862 Shares of Surmodics, Inc. $SRDXAugust 25, 2025 | marketbeat.comGTCR purchase of Surmodics would hurt medical device market, FTC saysAugust 22, 2025 | msn.comDLD Asset Management LP Sells 15,623 Shares of Surmodics, Inc. $SRDXAugust 22, 2025 | marketbeat.comMaven Securities LTD Invests $366,000 in Surmodics, Inc. $SRDXAugust 22, 2025 | marketbeat.comSurmodics (NASDAQ:SRDX) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?August 21, 2025 | marketbeat.comSurmodics FY2025 EPS Estimate Lifted by Barrington ResearchAugust 15, 2025 | marketbeat.comSRDX Stock Up Following Q3 Earnings Beat, Gross Margin ContractsAugust 12, 2025 | zacks.comSurModics: Hold Rating Amid Mixed Financial Performance and Legal UncertaintiesAugust 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIBN, SRDX, ANGO, ATRS, and ANIK Company DescriptionsAngioDynamics NASDAQ:ANGO$10.50 -0.15 (-1.41%) Closing price 04:00 PM EasternExtended Trading$10.50 0.00 (0.00%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.Anika Therapeutics NASDAQ:ANIK$8.65 -0.02 (-0.23%) Closing price 04:00 PM EasternExtended Trading$8.65 +0.00 (+0.06%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Antares Pharma NASDAQ:ATRSAntares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.SiBone NASDAQ:SIBN$15.14 -0.56 (-3.57%) Closing price 04:00 PM EasternExtended Trading$15.58 +0.44 (+2.90%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Surmodics NASDAQ:SRDX$32.37 +0.41 (+1.28%) Closing price 04:00 PM EasternExtended Trading$32.30 -0.07 (-0.22%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
